...
首页> 外文期刊>Journal of Medicinal Chemistry >Synthesis of Nitro Esters of Prednisolone, New Compounds Combining Pharmacological Properties of Both Glucocorticoids and Nitric Oxide
【24h】

Synthesis of Nitro Esters of Prednisolone, New Compounds Combining Pharmacological Properties of Both Glucocorticoids and Nitric Oxide

机译:泼尼松龙硝基酯的合成,结合糖皮质激素和一氧化氮的药理特性的新化合物

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Glucocorticoids (GC) are widely used in therapy for their many pharmacological properties including antiinflammatory and immunosuppressive actions. However, their use over long periods is hampered by a number of severe side effects. Given the biological properties of nitric oxide (NO) and previous experience with nonsteroidal antiinflammatory agents, we synthesized new chemical entities combining both NO and GC properties. Here we report the synthesis of nitro esters of prednisolone obtained through the esterification, with different linkers, on the hydroxy group at C-21 position of the corticosteroid structure. The alkyl chain, as of the nitrooxy derivative (2), or aromatic linkers, as of o-, m-, and p-nitrooxymethylbenzoate derivatives (3-5), respectively, furnish stable compounds that release NO and inhibit the GC receptors in biological assays. To improve solubility we introduced a more water-soluble linker such as the nitrooxyalkylpiperidine or -piperazine group (6-9). Also these compounds retained properties of both NO and prednisolone. Compound 5 (NCX 1015) was selected for its better profile: enhanced antiinflammatory properties and reduced side effects compared with prednisolone. NCX 1015 is currently under preclinical development.
机译:糖皮质激素(GC)因其许多药理特性(包括抗炎和免疫抑制作用)而广泛用于治疗中。但是,长期使用它们受到许多严重副作用的阻碍。鉴于一氧化氮(NO)的生物学特性和以前使用非甾体类抗炎药的经验,我们合成了结合NO和GC特性的新化学实体。在这里,我们报告了在皮质类固醇结构的C-21位置的羟基上,通过酯化反应获得的泼尼松龙硝基酯的合成,该酯化反应具有不同的接头。硝基氧基衍生物(2)的烷基链或邻硝基,间硝基和对硝基氧基甲基苯甲酸酯衍生物(3-5)的芳族连接基提供稳定的化合物,这些化合物可释放NO并抑制GC中的GC受体生物学测定。为了提高溶解度,我们引入了水溶性更强的连接基,例如硝基氧烷基哌啶或-哌嗪基团(6-9)。这些化合物还保留了NO和泼尼松龙的特性。选择化合物5(NCX 1015)是因为它具有更好的特性:与泼尼松龙相比,具有更强的抗炎特性和更低的副作用。 NCX 1015目前正在临床前开发中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号